US EditionCalquence combo recommended for approval in Europe for CLL
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Calquence combo recommended for approval in Europe for CLL
A European regulatory committee has recommended approval of a fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) for adults with previously untreated chronic lymphocytic leukemia (CLL), a type of blood cancer. The recommendation, from the Committee for Medicinal Products for Human Use, known as CHMP, covers Calquence combined with venetoclax (sold as Venclyxto in Europe and Venclexta in the U.S.), another CLL therapy. Gazyva (obin…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
